Belite Bio, Inc. ADR (BLTE) has released an update.
Belite Bio, Inc. has announced significant advancements in their second quarter with their novel oral treatment, Tinlarebant, showing promise in slowing disease progression in Stargardt Disease and Geographic Atrophy. The company has initiated and completed enrollment for phase 1b of the DRAGON II trial in Japan and is conducting a pivotal global Phase 3 trial with around 200 subjects enrolled. Financially, Belite Bio raised $25 million and reported a net loss increase, but remains optimistic as they prepare to share interim phase 3 trial analysis later in the year.
For further insights into BLTE stock, check out TipRanks’ Stock Analysis page.
